Podcasts about frcsc

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP In addition to heavy menstrual bleeding, patients with uterine fibroids often deal with many other considerable effects on their physical and mental wellbeing. To provide optimal care, it's important to recognize the full impact of fibroids, communicate carefully about treatment options, and promote equitable access to care. Dr. Charles Turck sits down with Dr. Ayman Al-Hendy to learn more about how we can address the multifaceted burden of uterine fibroids. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Send us a textThis week Fertility in Focus is thrilled to welcome Jullin Fjeldstad from Future Fertility and Dr. Sony Sierra from Evolve Egg Freezing Clinic, who sat down with us to discuss how they're bringing their unique expertise to the forefront of reproductive technology. These esteemed guests illuminate how AI is reshaping fertility preservation, specifically through the lens of egg freezing. Dr. Sierra provides a compelling overview of how egg freezing empowers individuals to align their reproductive plans with personal and professional aspirations, amidst a growing trend on social media. As more people turn to fertility preservation, understanding its benefits and implications becomes paramount. With insights from both of our guests this week, we explore how AI not only improves clinical outcomes but also offers patients unprecedented control and understanding over their fertility journeys.More about our guest speakers: Jullin Fjeldstad is the Head of Clinical Embryology and Scientific Operations at Future Fertility. Throughout her career, she has always held a passion for innovative ART technologies aimed at improving the fertility journey and IVF outcomes. In her current multi-faceted role, Jullin draws upon her experience as a seasoned embryologist and former lab director to navigate partnering clinics through seamless adoption of Future Fertility's AI-powered oocyte quality assessment tools, as well as overseeing Future Fertility's scientific project collaborations. With her extensive IVF experience and comprehensive understanding of the laboratory operations, she also provides invaluable input to the company's product development processes. Jullin holds a BSc. in Biology from the University of Victoria, Canada and a MSc. in Clinical Embryology from the University of Leeds, UK, where she achieved distinction in both areas.  Dr. Sony Sierra, MD, FRCSC, REI (She/Her), serves as a distinguished Reproductive Endocrinology & Infertility Specialist (REI) and Deputy Medical Director and Partner at TRIO. With nearly two decades of experience, she specializes in reproductive health, recurrent pregnancy loss, and early Recurrent Pregnancy Loss (RPL) programs. As the Medical Director at EVOLVE Egg Freezing Clinic and an Associate Physician at Women's College Hospital, she contributes significantly to advancing reproductive medicine. Dr. Sierra's research interests include infertility, implantation failure, and PCOS, reflected in her publications and conference presentations. Passionate about patient care, she approaches her practice with compassion and dedication, guided by her belief in excellence and empathy. Dr. Sierra's commitment to ongoing education and involvement in esteemed societies ensures her patients receive the most up-to-date care and expertise. She finds immense fulfillment in helping individuals and couples achieve their dreams of starting a family, making her a valued asset in the field of fertility medicine.For more info about Dr. Sierra, you can check out the TRIO Fertility Website: https://triofertility.com/team-member/sony-sierra/ or you can follow her on Instagram @drsonysierra. https://futurefertility.com/https://instagram.com/futurefertilityaihttps://www.youtube.com/@futurefertilityIf you or your organization would like to sponsor educational episodes just like this, please contact us at podcast@fertilitymatters.ca. Follow Fertility Matters Canada at @fertility_canada on Instagram and TikTok.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP Despite longstanding reliance on surgery, recent advancements have reshaped our approach to uterine fibroids. However, common myths and misconceptions have limited the adoption of newer therapies, leaving many patients unaware of their available options. Join Dr. Charles Turck and Dr. Ayman Al-Hendy as they explain shifting treatment paradigms and patient education strategies in uterine fibroid care. Dr. Al-Hendy is a Professor of Obstetrics and Gynecology and the Director of Translational Research at the University of Chicago Pritzker School of Medicine.

Shannon Salvador, MD, MSc, FRCSC - Advancing Frontline Endometrial Cancer Care: Translating the Latest Advances in Immunotherapy Plus Chemotherapy Regimens to Practice

Denise Black, MD, FRCSC / Marla Shapiro, C.M., MDCM, CCFP, MHSc, FRCPC, FCFP, MSCP - Navigating the Menopause Transition With Your Patients: Experts Answer Key Questions

Denise Black, MD, FRCSC / Marla Shapiro, C.M., MDCM, CCFP, MHSc, FRCPC, FCFP, MSCP - Navigating the Menopause Transition With Your Patients: Experts Answer Key Questions

Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care

Send us a textIn honour of Endometriosis Awareness Month, tune in to this republished, intriguing episode with Dr. Sony Sierra, a renowned reproductive endocrinologist at TRIO Fertility in Toronto and a past president of the Canadian Fertility and Endocrinology Society. Dr. Sierra takes us deep into endometriosis, shedding light on this misunderstood condition.Dr. Sony Sierra unpacks the realities of endometriosis—its overlooked symptoms, diagnostic challenges, and misunderstood impact on fertility. She breaks down the three key ways it affects conception, the best treatment options, and what patients need to know at every stage of their journey. This episode is a must-listen for anyone seeking clarity, support, and empowerment in the fight for endometriosis awareness.More About our Guest Speaker:Dr. Sony Sierra, MD, FRCSC, REI (She/Her), serves as a distinguished Reproductive Endocrinology & Infertility Specialist (REI) and Deputy Medical Director and Partner at TRIO. With nearly two decades of experience, she specializes in reproductive health, recurrent pregnancy loss, and early Recurrent Pregnancy Loss (RPL) programs. As the Medical Director at EVOLVE Egg Freezing Clinic and an Associate Physician at Women's College Hospital, she contributes significantly to advancing reproductive medicine. Dr. Sierra's research interests include infertility, implantation failure, and PCOS, reflected in her publications and conference presentations. Passionate about patient care, she approaches her practice with compassion and dedication, guided by her belief in excellence and empathy. Dr. Sierra's commitment to ongoing education and involvement in esteemed societies ensures her patients receive the most up-to-date care and expertise. She finds immense fulfillment in helping individuals and couples achieve their dreams of starting a family, making her a valued asset in the field of fertility medicine.For more info about Dr. Sierra, you can check out the TRIO Fertility Website: https://triofertility.com/team-member/sony-sierra/ or their Instagram at @triofertility. Follow Dr. Sierra directly at @drsonysierra.If you or your organization would like to sponsor educational episodes just like this, please contact us at podcast@fertilitymatters.ca. Follow Fertility Matters Canada at @fertility_canada on Instagram and TikTok.

AUA Guidelines: Diagnosis And Treatment Of Idiopathic Overactive Bladder Co-Host: Anne Pelletier Cameron, MD, FRCSC, URPS Segment #1: Is this an update to the prior Guideline? Segment #2: What is new in the Diagnosis, ntitial Assessment and Initial Management of OAB? Segment#3: What does the Guideline say about Oral Medication? Segment #4: What's new in minimally invasive prodcedures Segment #5: UDS and Cystoscopy Segment #6: What is new and exciting on the horizion for OAB Segment #7: Where to start and the most impactpact research in this area The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. Published online April 23, 2024. doi:10.1097/JU.0000000000003985. https://www.auajournals.org/doi/10.1097/JU.0000000000003985

Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion

Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion

Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion

In this episode of Clinical Lab Chat, Jeff Andrews, MD, FRCSC, BD's VP of Global Medical Affairs for Diagnostic Solutions, makes a return visit to the studio for a conversation with CLP's director of business intelligence, Chris Wolski, about BD and MD Anderson's collaboration on HPV sample self-collection study.  Among the topics they cover:How self-collection aids in the fight against cervical cancerThe importance of reaching underserved communitiesHow MD Anderson's program is shining a light on the need for sampling options in the U.S. and across the worldThe business benefits self-collection brings to labsThe impact self-collection will have in the near- and long-term

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJW865. CME/MOC/AAPA/IPCE credit will be available until November 8, 2025.Integrating Immunotherapy in Resectable NSCLC: How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc, Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJW865. CME/MOC/AAPA/IPCE credit will be available until November 8, 2025.Integrating Immunotherapy in Resectable NSCLC: How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc, Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJW865. CME/MOC/AAPA/IPCE credit will be available until November 8, 2025.Integrating Immunotherapy in Resectable NSCLC: How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc, Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJW865. CME/MOC/AAPA/IPCE credit will be available until November 8, 2025.Integrating Immunotherapy in Resectable NSCLC: How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc, Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJW865. CME/MOC/AAPA/IPCE credit will be available until November 8, 2025.Integrating Immunotherapy in Resectable NSCLC: How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc, Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJW865. CME/MOC/AAPA/IPCE credit will be available until November 8, 2025.Integrating Immunotherapy in Resectable NSCLC: How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc, Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Editor in Chief Cecelia E. Schmalbach, MD, MSc, is joined by senior author Julie E. Strychowsky MD, MAS, FRCSC, and Associate Editor Michael J. Brenner, MD, to discuss methods for improving the efficiency of ORs for surgeons as outlined in the paper “Improving Operating Room Efficiency in Otolaryngology–Head and Neck Surgery: A Scoping Review” which published in the October 2024 issue of Otolaryngology–Head and Neck Surgery. They discuss the importance of finding ways to save time and cost for operating rooms in order to serve more patients and reduce physician burnout. Click here to read the full article.    

Alon Altman, MD, FRCSC - Upping the Ante in Advanced Endometrial Cancer Care: Optimizing the Use of Immunotherapy to Improve Patient Outcomes

Editor’s choice: Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva Editorial: Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic Oncology Featuring: Dr Lilian T. Gien, MD, MSc, FRCSC, University of Toronto, Canada Dr Brenna Swift, MD, FRCSC, MSc, MASc, University of Toronto, Canada Dr Scott Glaser, MD, City of Hope, USA

Ask the Experts: New Guidelines in Spinal Cord Injury Brian K. Kwon, MD, PhD, FRCSC; Michael G. Fehlings, MD, PhD, FRCSC; Rajiv Saigal, MD, PhD; Yi Lu, MD, PhD

Dr. James A. Simon is a highly accomplished and respected physician dedicated to advancing research and clinical care in women's sexual and reproductive health. This is his second appearance on our Menopause Reimagined Podcast. The link to his first interview can be found below. We posted a short video, and our viewers asked many questions. So Andrea Donsly, nutritionist, menopause researcher, menopause educator, and co-found of Morphus, invited Dr. Simon back to answer all your questions about Urinary Tract Infections.

In this episode of SurgOnc Today ®, Alex Parikh, MD, MPH, FACS, FSSO, from the University of Texas – San Antonio and Julie Hallet, MD, M.Sc., FRCSC, FSSO from the University of Toronto are joined by Monica M. Dua, MD, from Stanford University and Ching-Wei Tzeng, , MD, FACS, FSSO, from the MD Anderson Cancer Center. They will be discussing two important aspects of the surgical management of perihilar cholangiocarcinoma: strategies for pre-operative optimization and biliary drainage, and management of the future liver remnant. This is part one of a two-part series.

Authors Michael G. Fehlings, MD, PhD, FRCSC and Karlo M. Pedro, MD discuss the intricacies of their new SpineLine article, "The Shifting Demographics of Spinal Cord Injury: Important Implications for Medicine and Society," with moderator Kaku Barkoh, MD. Fehlings is an orthopedic surgeon and Pedro is a neurosurgeon. Both are at the University of Toronto; Barkoh is an orthopedic surgeon at Orthopaedic Associates, LLP. in Houston, Texas.

In this episode of SurgOnc Today®, Julie Hallet, MD, MSc, FRCSC, FSSO, from the University of Toronto and Vice-Chair of the SSO HPB disease site working group is joined by Stefano Partelli, MD, PhD, from Università Vita-Saluta San Raffaele and Els Nieveen van Dijkum, MD, PhD, from Amsterdam UMC. We will delve into the rationale behind the non-operative management of non-functional sporadic pancreatic neuroendocrine tumors (PNETs) as well as the design and results of two prospective studies, ASPEN and PANDORA. Show Notes: PANDORA: https://academic.oup.com/bjs/article/108/8/888/6202974 ASPEN (interim analysis): https://academic.oup.com/bjs/article/109/12/1186/6672718?login=false

I was recently honored to be a guest speaker among the innovators, stakeholders, and pioneering minds in managing benign prostate hyperplasia at the annual assembly of the Society of Benign Prostate Disease, held in Dallas this February.  Today, I am delighted to have one of the Society of Benign Prostate Disease board of directors, Dr. Kevin Zorn, joining me to share an insider perspective as we review the key takeaways from the meeting and bring you up to speed on the latest technologies for evaluating and managing BPH. We will also offer a sneak peek into several new advancements coming down the pipeline.  Dr. Kevin Zorn, from the BPH Canada Clinic in Montreal, is a board-certified urologist and former Associate Professor of Urology at the Universities of Montreal and Chicago, sub-specializing in robotic surgery and BPH surgical care. Throughout his career, Dr. Zorn has been committed to research and innovation. He was the first in Canada and Quebec to use many new BPH technologies, including Greenlight XPS, Rezum, ITind, Optilume, and aquablation. Dr. Zorn is a senior author of the BPH guidelines for the Canadian Urological Association, having authored 345 peer-reviewed publications and 12 book chapters on BPH and minimally invasive surgical care. He has lectured, taught, and practiced surgery globally and is intimately involved in developing several new pioneering BPH technologies. Stay tuned for the latest insights and breakthroughs as we unveil the future of BPH management. Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show Highlights: Dr. Zorn shares some highlights from his presentation on the evaluation of BPH in the modern clinic setting How new technology, like mobile apps and point-of-care ultrasound, can improve the diagnosis and treatment times for BPH Explanation of the UroCuff technology Discussion of the latest technology that has been available over the last year for interventional management of BPH The importance of knowing the personal preferences of patients when selecting their treatment options for BPH The benefits of aquablation technology Dr. Zorn discusses the evolution of BPH treatment Why urologists must remain flexible in their approach to BPH care The importance stay up-to-date with the latest BPH technology and guidelines The potential of AI to empower urologists and improve patient care Links:  Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd  Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. BPH Canada  Society of Benign Prostate Disease

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

AOA President Ann Van Heest, MD, FAOA, connected with Canadian Orthopaedic Association (COA) Past President, Laurie Hiemstra, MD, PhD, FRCSC, to discuss her unusual path to leadership, her plan for improving diversity in orthopaedics, and the most pressing critical issues affecting the COA. While waitlisting and licensure issues between provinces continue to be a challenge within the orthopaedic specialty, Dr. Hiemstra made it her goal to advocate for underrepresented groups, unify the community, and help develop competent young orthopaedic leaders. 

In this episode, we have two of the Urology Care Foundation's Humanitarian Grant Program Recipients with us to talk about their passion for helping bring care to others. The work these doctors do across the world helps the lives of patients and their families. Listen along as Rajiv K. Singal, MD, FRCSC and Dana Weiss, MD share their stories. For more information about Humanitarians in Urology, check out our website here: https://www.urologyhealth.org/humanitarianism/humanitarians-in-urology. For more information about urology, please visit www.urologyhealth.org/ and don't forget to subscribe to our free digital magazine, UrologyHealth extra at https://www.urologyhealth.org/healthy-living/urologyhealth-extra. **** November 9, 2023

It's pulmonary hypertension month on JHLT: The Podcast! The JHLT Digital Media Editors explore two PVD-related manuscripts from the November issue of The Journal of Heart and Lung Transplantation. Digital Media Editor Marty Tam, MD, assistant professor in the division of cardiovascular medicine at the University of Michigan, hosts this episode.   First, hear from first author Zvonimir Rako, MD, on his team's study “Clinical and functional relevance of right ventricular contraction patterns in pulmonary hypertension.”   The right ventricle (RV) has a complex contraction pattern. For patients with pulmonary hypertension (PH), right ventricular to pulmonary artery (RV-PA) coupling is important when considering how the RV responds to increases in afterload. Uncoupling occurs with progressive disease and the degree of uncoupling can be derived from pressure–volume loop analysis as the ratio between end-systolic and arterial elastance (Ees/Ea).   In this exploratory analysis of the prospective EXERTION study, the authors determined the relationship between RV contraction patterns and RV-PA coupling in patients with PH. They also correlated RV contraction patterns to hemodynamic risk profiles. For details on what the study found about how PH programs can use the results in their practice, listen to the discussion in the episode.   Next, the editors explored the study “Impact of sex on outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.” The podcast hosted first author Justin C.Y. Chan, MD, MPhil and senior author Marc de Perrot,  MD, MSc, FRCSC.   The impact of sex on long-term outcomes after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension (CTEPH) has remained unclear. The authors of this study sought to evaluate the early and long-term outcomes after pulmonary endarterectomy to see if sex had an impact on the risk of residual pulmonary hypertension and need for targeted PH medical therapy.    For details on what this retrospective single-center study found, including the mechanics of sex differences and the potential changes to clinical approach, check out the episode.   Follow along at www.jhltonline.org/current, or, if you're an ISHLT member, log in at ishlt.org/journal-of-heart-lung-transplantation.  Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

This session will review state of the art therapy for peritoneal mesothelioma. The discussion includes cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as well as systemic chemotherapy and immunotherapy. Edward Levine, MD, moderates this podcast and is Professor of Surgery and Chief, Surgical Oncology at Wake Forest University. Trang Nguyen, MD, is an Assistant Professor of Surgery at Indiana University and Sinziana Dumitra, MD, MSc, FRCSC, FSSO, is an Assistant Professor of Surgery at McGill University. 

2023 OJSM William A. Grana Award for Best Research Paper spotlight - Dr. Olufemi Ayeni from McMaster University Medical Centre in Ontario joins us to discuss his award-winning study “Effect of Osteochondroplasty on Time to Reoperation After Arthroscopic Management of Femoroacetabular Impingement: Analysis of a Randomized Controlled Trial." As hip arthroscopy continues to grow as a beneficial treatment option in Sports Medicine, high level evidence is needed to support its efficacy.  Dr. Ayeni and his group provide high quality data supporting the long term benefits of osteochondroplasty versus soft tissue work alone.

This series is part of the work I'm doing with Weight Inclusive Nutrition and Dietetics (WIND) to create a comprehensive response to the disastrous American Academy of Pediatrics (AAP) guidelines for higher-weight children. I'm part of the team that is analyzing the research that, the AAP claims, supports their recommendations, and I'll be publishing my breakdowns here as well.Today's study is Laparoscopic sleeve gastrectomy in children younger than 14 years: refuting the concernsAayed Alqahtani, MD, FRCSC, FACS, Mohamed Elahmedi, MBBS, and Awadh R. Al Qahtani, MD, MSc, FRCSC Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

The power of scientific collaboration has a broad reach. During the COVID-19 pandemic, more than 7000 clinical trials were registered, with more than 100 different countries represented. Samantha Gambles Farr, MSN, NP-C, CCRN, RNFA, was joined by SCCM Lifetime Achievement Award Recipient John C. Marshall, MD, FRCSC, FACS, at the 2023 Critical Care Congress to discuss the importance of research and scientific collaboration. Dr. Marshall has been involved in research programs with researchers around the globe and is a well-known speaker with nearly 600 published manuscripts. This podcast is sponsored by Dompe Pharmaceutical.

Playing Well with the Boys Hosted by Ashley Amalfi, MD, with Guest Speakers Michael Neumeister MD, FRCSC, FACS and Paul Cederna, MD.                                                                                            LIMITLESS Leaders Podcast is made Possible with the support of  Allergan Aesthetics

In this episode of SurgOnc Today, Alexander Parikh MD, MPH, FACS, FSSO, from the University of Texas, San Antonio and Chair of the SSO HPB Disease Site Work Group, and Julie Hallet, MD, M.Sc., FRCSC, from the University of Toronto, and Vice-Chair of the SSO HPB Disease Site Work Group, are joined by Flavio G. Rocha, MD, FACS, FSSO, from the Oregon Health and Science University and Susanne G. Warner, MD, from the Mayo Clinic Rochester. They discuss two important aspects of delivering neoadjuvant therapy for pancreatic adenocarcinoma: the use of staging laparoscopy and the assessment of response. 

We welcome Dr. Daniel Whelan, Head of University of Toronto Sports Medicine, to discuss his team's recent publication “Assessment of 30 Years of Randomized Controlled Trials in The American Journal of Sports Medicine: 1990-2020.” This critical look at how our very best clinical studies have changed over a 30-year period is a fascinating reflection of our own evolution as orthopaedic sports medicine specialists. The past informs the present and can teach us lessons on how to be better in the future. 

Ticiana De Francesco, MD, shares an update on the first-in-human experience with femtosecond laser image-guided high-precision trabeculotomy, or FLIGHT (ViaLase), as covered in an article she coauthored with Iqbal Ike K. Ahmed, MD, FRCSC, for an upcoming issue of Glaucoma Today. Dr. De Francesco describes the new procedure and how it could help expand options for safe and effective glaucoma intervention.

This week the fellas have the pleasure of speaking with Sean Christie, MD, FRCSC, a renowned neurosurgeon and expert in making operating rooms more environmentally sustainable. Sean is a professor, vice chair, and director of research at the division of neurosurgery at Dalhousie University. Operating rooms are known to generate large amounts of waste and consume significant amounts of energy and resources. Sean shares with us his insights on the importance of creating more eco-conscious operating rooms and the benefits it can bring not only to the environment but also to patient care and hospital finances. Through his expertise and experience, Sean demonstrates how making operating rooms more eco-friendly can have a significant impact on reducing the healthcare industry's environmental footprint and promoting a healthier and more sustainable future for all. Join the post-episode conversation over on Discord! https://discord.gg/expeUDN